|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sturgis EM, Wei Q and Spitz MR:
Descriptive epidemiology and risk factors for head and neck cancer.
Semin Oncol. 31:726–733. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Blot WJ, McLaughlin JK, Winn DM, Austin
DF, Greenberg RS, Preston-Martin S, Bernstein L, Schoenberg JB,
Stemhagen A and Fraumeni JF Jr: Smoking and drinking in relation to
oral and pharyngeal cancer. Cancer Res. 48:3282–3287.
1988.PubMed/NCBI
|
|
4
|
Grandis JR and Tweardy DJ: Elevated levels
of transforming growth factor alpha and epidermal growth factor
receptor messenger RNA are early markers of carcinogenesis in head
and neck cancer. Cancer Res. 53:3579–3584. 1993.PubMed/NCBI
|
|
5
|
Scaltriti M and Baselga J: The epidermal
growth factor receptor pathway: A model for targeted therapy. Clin
Cancer Res. 12:5268–5272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iqbal N and Iqbal N: Imatinib: A
breakthrough of targeted therapy in cancer. Chemother Res Pract.
2014:3570272014.PubMed/NCBI
|
|
7
|
Harvey RD, Adams VR, Beardslee T and
Medina P: Afatinib for the treatment of EGFR mutation-positive
NSCLC: A review of clinical findings. J Oncol Pharm Pract.
26:1461–1474. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu ZQ, Zhang Y, Li N, Liu PJ, Gao L, Gao X
and Tie XJ: Efficacy and safety of lapatinib and trastuzumab for
HER2-positive breast cancer: A systematic review and meta-analysis
of randomised controlled trials. BMJ Open. 7:e0130532017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vermorken JB, Trigo J, Hitt R, Koralewski
P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A and
Baselga J: Open-label, uncontrolled, multicenter phase II study to
evaluate the efficacy and toxicity of cetuximab as a single agent
in patients with recurrent and/or metastatic squamous cell
carcinoma of the head and neck who failed to respond to
platinum-based therapy. J Clin Oncol. 25:2171–2177. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ferrarotto R and Gold KA: Afatinib in the
treatment of head and neck squamous cell carcinoma. Expert Opin
Investig Drugs. 23:135–143. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cohen RB: Current challenges and clinical
investigations of epidermal growth factor receptor (EGFR)- and ErbB
family-targeted agents in the treatment of head and neck squamous
cell carcinoma (HNSCC). Cancer Treat Rev. 40:567–577. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kozakiewicz P and Grzybowska-Szatkowska L:
Application of molecular targeted therapies in the treatment of
head and neck squamous cell carcinoma. Oncol Lett. 15:7497–7505.
2018.PubMed/NCBI
|
|
13
|
Weiss JM, Bagley S, Hwang WT, Bauml J,
Olson JG, Cohen RB, Hayes DN and Langer C: Capecitabine and
lapatinib for the first-line treatment of metastatic/recurrent head
and neck squamous cell carcinoma. Cancer. 122:2350–2355. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Agarwal V, Subash A, Nayar RC and Rao V:
Is EGFR really a therapeutic target in head and neck cancers? J
Surg Oncol. 119:685–686. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cohen EE, Licitra LF, Burtness B, Fayette
J, Gauler T, Clement PM, Grau JJ, Del Campo JM, Mailliez A, Haddad
RI, et al: Biomarkers predict enhanced clinical outcomes with
afatinib versus methotrexate in patients with second-line recurrent
and/or metastatic head and neck cancer. Ann Oncol. 28:2526–2532.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Picon H and Guddati AK: Mechanisms of
resistance in head and neck cancer. Am J Cancer Res. 10:2742–2751.
2020.PubMed/NCBI
|
|
17
|
Shuford S, Lipinski L, Abad A, Smith AM,
Rayner M, O'Donnell L, Stuart J, Mechtler LL, Fabiano AJ, Edenfield
J, et al: Prospective prediction of clinical drug response in
high-grade gliomas using an ex vivo 3D cell culture assay.
Neurooncol Adv. 3:vdab0652021.PubMed/NCBI
|
|
18
|
Costa EC, Moreira AF, de Melo-Diogo D,
Gaspar VM, Carvalho MP and Correia IJ: 3D tumor spheroids: An
overview on the tools and techniques used for their analysis.
Biotechnol Adv. 34:1427–1441. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Prince ME, Sivanandan R, Kaczorowski A,
Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF and Ailles
LE: Identification of a subpopulation of cells with cancer stem
cell properties in head and neck squamous cell carcinoma. Proc Natl
Acad Sci USA. 104:973–978. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Clay MR, Tabor M, Owen JH, Carey TE,
Bradford CR, Wolf GT, Wicha MS and Prince ME: Single-marker
identification of head and neck squamous cell carcinoma cancer stem
cells with aldehyde dehydrogenase. Head Neck. 32:1195–1201. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tahmasebi E, Alikhani M, Yazdanian A,
Yazdanian M, Tebyanian H and Seifalian A: The current markers of
cancer stem cell in oral cancers. Life Sci. 249:1174832020.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamada KM and Cukierman E: Modeling tissue
morphogenesis and cancer in 3D. Cell. 130:601–610. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ayuso JM, Vitek R, Swick AD, Skala MC,
Wisinski KB, Kimple RJ, Lambert PF and Beebe DJ: Effects of culture
method on response to EGFR therapy in head and neck squamous cell
carcinoma cells. Sci Rep. 9:124802019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chan YH, Lee YC, Hung CY, Yang PJ, Lai PC
and Feng SW: Three-dimensional spheroid culture enhances
multipotent differentiation and stemness capacities of human dental
pulp-derived mesenchymal stem cells by modulating MAPK and NF-kB
signaling pathways. Stem Cell Rev Rep. 17:1810–1826. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee HK, Noh MH, Hong SW, Kim SM, Kim SH,
Kim YS, Broaddus VC and Hur DY: Erlotinib activates different cell
death pathways in EGFR-mutant lung cancer cells grown in 3D versus
2D culture systems. Anticancer Res. 41:1261–1269. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
DelNero P, Lane M, Verbridge SS, Kwee B,
Kermani P, Hempstead B, Stroock A and Fischbach C: 3D culture
broadly regulates tumor cell hypoxia response and angiogenesis via
pro-inflammatory pathways. Biomaterials. 55:110–118. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fontoura JC, Viezzer C, Dos Santos FG,
Ligabue RA, Weinlich R, Puga RD, Antonow D, Severino P and Bonorino
C: Comparison of 2D and 3D cell culture models for cell growth,
gene expression and drug resistance. Mater Sci Eng C Mater Biol
Appl. 107:1102642020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schmidt M, Scholz CJ, Polednik C and
Roller J: Spheroid-based 3-dimensional culture models: Gene
expression and functionality in head and neck cancer. Oncol Rep.
35:2431–2440. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Imamura Y, Mukohara T, Shimono Y,
Funakoshi Y, Chayahara N, Toyoda M, Kiyota N, Takao S, Kono S,
Nakatsura T and Minami H: Comparison of 2D- and 3D-culture models
as drug-testing platforms in breast cancer. Oncol Rep.
33:1837–1843. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mosaad E, Chambers K, Futrega K, Clements
J and Doran MR: Using high throughput microtissue culture to study
the difference in prostate cancer cell behavior and drug response
in 2D and 3D co-cultures. BMC Cancer. 18:5922018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Watanabe S, Yonesaka K, Tanizaki J,
Nonagase Y, Takegawa N, Haratani K, Kawakami H, Hayashi H, Takeda
M, Tsurutani J and Nakagawa K: Targeting of the HER2/HER3 signaling
axis overcomes ligand-mediated resistance to trastuzumab in
HER2-positive breast cancer. Cancer Med. 8:1258–1268. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Temraz S, Mukherji D and Shamseddine A:
Dual targeting of HER3 and EGFR in colorectal tumors might overcome
anti-EGFR resistance. Crit Rev Oncol Hematol. 101:151–157. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang D, Qian G, Zhang H, Magliocca KR,
Nannapaneni S, Amin AR, Rossi M, Patel M, El-Deiry M, Wadsworth JT,
et al: HER3 targeting sensitizes HNSCC to cetuximab by reducing
HER3 activity and HER2/HER3 dimerization: Evidence from cell line
and patient-derived xenograft models. Clin Cancer Res. 23:677–686.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Iida M, Bahrar H, Brand TM, Pearson HE,
Coan JP, Orbuch RA, Flanigan BG, Swick AD, Prabakaran PJ, Lantto J,
et al: Targeting the HER family with Pan-HER effectively overcomes
resistance to cetuximab. Mol Cancer Ther. 15:2175–2186. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
von der Grün J, Rödel F, Brandts C, Fokas
E, Guckenberger M, Rödel C and Balermpas P: Targeted therapies and
immune-checkpoint inhibition in head and neck squamous cell
carcinoma: Where do we stand today and where to go? Cancers
(Basel). 11:4722019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Guo Y, Ahn MJ, Chan A, Wang CH, Kang JH,
Kim SB, Bello M, Arora RS, Zhang Q, He X, et al: Afatinib versus
methotrexate as second-line treatment in Asian patients with
recurrent or metastatic squamous cell carcinoma of the head and
neck progressing on or after platinum-based therapy (LUX-head &
neck 3): an open-label, randomised phase III trial. Ann Oncol.
30:1831–1839. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Phan TG and Croucher PI: The dormant
cancer cell life cycle. Nat Rev Cancer. 20:398–411. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Faber A, Aderhold C, Goessler UR, Hoermann
K, Schultz JD, Umbreit C, Walliczek U and Stern-Straeter J:
Interaction of a CD44+ head and neck squamous cell carcinoma cell
line with a stromal cell-derived factor-1-expressing supportive
niche: An in vitro model. Oncol Lett. 7:82–86. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lammert A, Affolter A, Gvaramia D, Heid J,
Jungbauer F, Scherl C, Tenschert E, Rotter N, Willett N and Kern J:
The tumor stem cell niche of head and neck-point of intersection
with therapeutic potential? Laryngorhinootologie. 100:23–29.
2021.(In German). PubMed/NCBI
|
